MedTrace Logo

Carnosine Supplementation on Quantity/Quality of Oral Salivae.

NCT04295525 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-05-18

No results posted yet for this study

Summary

The aim of this study is to elucidate the mutual relationship between salivae characteristics and oral microbiome and to compare them with common oral disease; furthermore, by using specific bioinformatic tools to analyse the data, the potentials of Carnosine in preventing/treating oral diseases and its mechanism of action will be addressed by using quantitative proteomics.

Conditions

  • Oral Diseases

Interventions

DIETARY_SUPPLEMENT

400 mg mucoadhesive oral tablet

AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)

DIETARY_SUPPLEMENT

placebo mucoadhesive oral tablet

placebo

Sponsors & Collaborators

  • University of Milan

    lead OTHER

Principal Investigators

  • Michele Ciulla, MD · Lab. Clin. Informatics & Cardiovascular Imaging, University of Milan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04295525 on ClinicalTrials.gov